Evolus, Inc.
EOLS
$0.02
Change (1 day)
$17.82
Year High
$9.80
Year Low
Categories
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
P/B ratio for Evolus, Inc. (EOLS)
P/B ratio as of 2023: -28.97
According to Evolus, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is -28.97. At the end of 2022 the company had a P/B ratio of 22.76.
P/B ratio history for Evolus, Inc. from 2015 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | -28.97 |
| 2022 | 22.76 |
| 2021 | -0.77 |
| 2020 | -0.30 |
| 2019 | -1.61 |
| 2018 | -2.36 |
| 2017 | -3.59 |
| 2016 | -30.09 |
| 2015 | 17.82 |